<DOC>
	<DOCNO>NCT00188149</DOCNO>
	<brief_summary>Prognosis patient Hodgkin´s lymphoma ( HL ) improve significantly last decade . Therefore , impact treatment associate long-term toxicity late effect second cancer increase . The purpose prospective multicenter trial show feasibility treatment ABVD alone patient limited stage ( HL1 ) intermediate stage ( HL2 ) disease intensify etoposide-free chemotherapy regimen patient advanced disease ( HL3 ) include 18F-FDG-PET evaluation .</brief_summary>
	<brief_title>Optimization Primary Therapy Patients With Hodgkin 's Disease Evaluation PET</brief_title>
	<detailed_description>The aim limited intermediate stage reduce toxicity omit subsequent radiotherapy patient complete remission ABVD chemotherapy . Patients limited disease receive four cycle , patient intermediate disease ( accord criterion German Hodgkin Study group , GHSG ) receice six cycle ABVD . In case residual mass ( &gt; 1.5 cm ) , additional involved field irradiation plan . The aim advance disease use BACOPP-D regimen include cyclophosphamide , adriamycin , dacarbazine , procarbazine , prednisolone , bleomycin vincristine , reduce hematological toxicity secondary leukemia omit etoposide ( comparison BEACOPP escalate regimen ) . All patient receive eight cycle BACOPP-D regimen . In case residual mass ( &gt; 1.5 cm ) , additional involved field irradiation plan . Additionally , want evaluate CT- PET-based remission status chemotherapy final staging .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion Criteria ( HL1 ) : Histologically confirm Hodgkin´s Lymphoma ( WHO Classification 1999 ) 1 . Classical Hodgkin Lymphoma : Nodular sclerosis ( type 1 2 ) / Mixed type / Lymphocyte deplete type / Lymphocyte rich type 2 . Nodular lymphocytepredominant Hodgkin Lymphoma Patients stage : Clinical stage ( CS ) I without risk factor / CS II without risk factor Age 16 75 Written inform consent Inclusion criterion ( HL2 ) : Histologically confirm Hodgkin´s Lymphoma ( WHO Classification 1999 ) 1 . Classical Hodgkin´s Lymphoma : Nodular sclerosis ( type 1 2 ) / Mixed type / Lymphocyte deplete type / Lymphocyte rich type 2 . Nodular lymphocytepredominant Hodgkin Lymphoma Patients stage 1 . Clinical stage ( CS ) I , II A risk factor : Large mediastinal tumor ( &gt; 1/3 maximal diameter thoracic cavity ) / Extranodal disease / Sedimentation rate ≥ 50 mm/h patient without Bsymptomes ≥ 30 mm/h patient Bsymptomes / ≥ 3 lymph node area infiltrate tumor cell 2 . Clinical stage ( CS ) II B risk factor : Sedimentation rate ≥ 50 mm/h patient without Bsymptomes ≥ 30 mm/h patient Bsymptomes / ≥ 3 lymph node area infiltrate tumor cell Age 16 75 Written inform consent Inclusion criterion ( HL3 ) : Histologically confirm Hodgkin´s Lymphoma ( WHO Classification 1999 ) 1 . Classical Hodgkin 's Lymphoma ( Hodgkin 's desease ) : Nodular sclerosis ( type 1 2 ) / Mixed type / Lymphocyte deplete type / Lymphocyte rich type 2 . Nodular lymphocytepredominant Hodgkin Lymphoma Patients stage 1 . Clinical stage ( CS ) II B minimum one follow risk factor : Large mediastinal tumor ( ≥1/3 maximal diameter thoracic cavity ) / Extranodal disease 2 . Clinical stage ( CS ) III 3 . Clinical stage ( CS ) IV Age 16 65 Written inform consent Exclusion Criteria ( HL1 , HL2 HL3 ) : Poor general condition relate lymphoma ( ECOG perfomance status 3 4 ; Karnofsky Index &lt; 50 % ) Severe concomitant disease : cardiac insufficiency ( NYHA grade III IV ) / chronic respiratory insufficiency hypoxemia / Hepatic insufficiency ( cirrhosis , Hepatitis B C / chronic renal insufficiency / HIV infection outofcontrol infection / hematopoetic insufficiency ( Leukocytes &lt; 3000/µl ; Thrombocytes &lt; 100.000/µl / psychiatric disease History previous malignancy last 5 year Pregnancy Patients likely comply requirement stem form participation trial</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>PET</keyword>
</DOC>